News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acceleron Pharma Secures $30 Million Private Financing


12/28/2011 6:23:53 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private financing. Celgene, one of Acceleron’s strategic partners, and all other existing investors participated in this financing. The proceeds will be used to expand and advance Acceleron’s clinical stage pipeline and to continue to support its highly productive research engine.

“This fortifies Acceleron’s solid financial position and provides the Company with the resources to continue to advance and expand our robust clinical and preclinical pipeline”, said John Knopf, Ph.D., Chief Executive Officer of Acceleron. “We’re especially pleased with Celgene’s commitment to Acceleron as we jointly develop several promising products for the treatment of anemia.”

In conjunction with this financing, George Golumbeski, Senior Vice President of Corporate Development of Celgene, has joined the Acceleron Board of Directors.

About Acceleron

Acceleron is a privately-held biopharmaceutical company committed to discover, develop, manufacture and commercialize novel protein therapeutics for orphan diseases and cancer. Acceleron’s scientific approach takes advantage of its unique insight to discover first-in-class therapies based on the TGF-ß protein superfamily. Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to advance its therapeutic programs rapidly and efficiently. The investors in Acceleron include Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. For further information on Acceleron, please visit www.acceleronpharma.com.

Contact:

Acceleron Pharma:

Steven Ertel, 617-649-9234

Senior Vice President, Corporate Development

or

Maureen L. Suda (Media)

Suda Communications LLC, 585-387-9248


Read at BioSpace.com
Read at Boston Business Journal
Read at Xconomy

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES